Oxford BioMedica's TroVax To Be Tested In Asbestos Cancer

24th Jun 2010 07:50

LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Thursday said it has teamed up with scientists in Wales to test its experimental cancer vaccine TroVax in patients with mesothelioma, a cancer of the lung lining linked to exposure to asbestos. Oxford BioMedica said it entered a collaboration with a team from Cardiff University and the city's Velindre Cancer Centre to evaluate TroVax as a treatment for mesothelioma in a small study. The trial will be funded by the June Hancock Mesothelioma Research Fund, a charity. -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; [email protected] (END) Dow Jones Newswires June 24, 2010 02:50 ET (06:50 GMT)

Top Risers

Share	Price	Change
Oracle Power (ORCP)	0.065	30%
Silver Bullet (SBDS)	22.50	18.42%
Active Energy (AEG)	0.0915	18.06%
Sareum (SAR)	21.50	16.22%
Rank Group Plc (RNK)	104.20	15.27%

Top Fallers

Share	Price	Change
PipeHawk (PIP)	2.25	-30.77%
Trellus Health. (TRLS)	0.20	-20%
Empyrean (EME)	0.0675	-18.67%
Sabien Tech. (SNT)	6.50	-16.13%
Proservice Bldg (PRO)	4.19	-15.52%

Top By Volume

Share	Price	Volume
Oracle Power (ORCP)	0.065	1,590,360,606
Premier African Minerals (PREM)	0.016	569,709,190
Tower Resources (TRP)	0.026	458,442,076
Quantum Helium (QHE)	0.0425	423,183,781
Empyrean (EME)	0.0675	369,720,061

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.